Select Language:
A diabetes medication developed by a Chinese pharmaceutical company, in partnership with Sinovac Biotech, has gained regulatory approval for sale in Peru. The country’s health authorities recently authorized the marketing of Liraglutide injections, a drug that acts as a glucagon-like peptide-1 receptor agonist to help manage blood sugar levels in individuals with type 2 diabetes. The medication can be administered as a standalone treatment or combined with other diabetes therapies.
This medication was independently created by the Chinese company and received approval from China’s National Medical Products Administration in December 2023, marking it as the second domestically produced drug of this type to secure such authorization.
The company invested over ten years and approximately CNY240 million (around USD33.9 million) into its research and development efforts.
In late 2022, the company and Sinovac agreed to collaborate on promoting Liraglutide internationally, with Sinovac obtaining rights to market the drug across 17 emerging markets.
Earlier this year, the drug underwent a good manufacturing practice audit conducted on-site by Egypt’s Ministry of Health. It received a GMP certification from Colombia’s regulatory institute in April and was recently audited once more on-site by Brazil’s health agency this month.
ChatGPT
Perplexity
Gemini AI
Grok AI
